AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation products, will release its financial results
for the first quarter ended March 31, 2009 on Tuesday, May 5, 2009 and
management will host a conference call at 10:00 a.m. Eastern Time. A
live webcast of the conference call will be available from the investor
relations page of AtriCure’s corporate web site, www.atricure.com.
Pre-registration is available and recommended for this call at the
following URL:
https://www.theconferencingservice.com/prereg/key.process?key=P9UGV8H3A
You may also be placed into the call by an operator by calling
888-713-4214 for domestic callers and 617-213-4866 for international
callers at least 15 minutes prior to the call start time using
reservation code 10407486.
The webcast will be available on AtriCure’s web site and a telephonic
replay of the call will also be available through June 5, 2009. The
replay dial-in numbers are 888-286-8010 for domestic callers and
617-801-6888 for international callers, using reservation code 65958936.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing,
manufacturing and selling innovative cardiac surgical ablation systems
designed to create precise lesions, or scars, in cardiac, or heart,
tissue. Medical journals have described the adoption by leading
cardiothoracic surgeons of the AtriCure Isolator® bipolar
ablation system as a treatment alternative during open-heart surgical
procedures to create lesions in cardiac tissue to block the abnormal
electrical impulses that cause atrial fibrillation, or AF, a rapid,
irregular quivering of the upper chambers of the heart. Additionally,
medical journals and leading cardiothoracic surgeons have described the
AtriCure Isolator system as a promising treatment alternative
for patients who may be candidates for sole-therapy minimally invasive
procedures. AF affects more than 5.5 million people worldwide and
predisposes them to a five-fold increased risk of stroke. The FDA has
cleared the AtriCure Isolator system and AtriCure’s multifunctional pen
and CoolrailTM linear ablation device, for the ablation, or
destruction, of cardiac tissue during surgical procedures. Additionally,
the FDA has cleared AtriCure’s multifunctional pen for temporary pacing,
sensing, stimulating and recording during the evaluation of cardiac
arrhythmias and AtriCure’s Cryo1TM system for the
cryosurgical treatment of cardiac arrhythmias. To date, the FDA has not
cleared or approved AtriCure’s products for the treatment of AF.
AtriCure, Inc.
Julie A. Piton
Vice President and
Chief Financial Officer
513-755-4561
jpiton@atricure.com
